The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 23, 2019

Filed:

Oct. 21, 2011
Applicants:

Leo Timothy Laughlin, Ii, Mason, OH (US);

Tomohiro Hakozaki, Cincinnati, OH (US);

Wenzhu Zhao, Mason, OH (US);

Jiazhen Wang, Dayton, OH (US);

John Crist Bierman, Colerain Township, OH (US);

Inventors:

Leo Timothy Laughlin, II, Mason, OH (US);

Tomohiro Hakozaki, Cincinnati, OH (US);

Wenzhu Zhao, Mason, OH (US);

Jiazhen Wang, Dayton, OH (US);

John Crist Bierman, Colerain Township, OH (US);

Assignee:

The Procter & Gamble Company, Cincinnati, OH (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/02 (2006.01); C07C 257/18 (2006.01); C07C 233/51 (2006.01); C07D 471/10 (2006.01); C07D 405/14 (2006.01); C07D 209/88 (2006.01); C07D 459/00 (2006.01); G01N 21/64 (2006.01); C07C 229/52 (2006.01); G01N 33/566 (2006.01);
U.S. Cl.
CPC ...
G01N 33/566 (2013.01); G01N 2500/10 (2013.01);
Abstract

Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADRβ1 receptors, and determining based on the binding interaction of the test agent with the ADRβ1 receptors whether the test agent is an effective ADRβ1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADRβ1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.


Find Patent Forward Citations

Loading…